Table 1.

Demographic and clinical characteristics of the entire sample (baseline sample; Study 1 + Study 2), the subjects with pre- post-L-DOPA treatment scales (L-DOPA sample; Study 2), and the subjects with pre- and post-L-DOPA treatment NM-MRI (follow-up subgroup; Study 2 subset).

Characteristic	Baseline sample (N = 33; Study 1 + Study 2)	L-DOPA sample (N = 15; Study 2)	Follow-up subgroup (N = 6; Study 2 subset)	Test Statistica	P-valuea
Age (years)	71.8 ± 6.5	72.7 ± 6.3	73.7 ± 5.5	25.5	0.89
Sex (female)	21 (63.6%)	9 (60%)	4 (66.7%)	0.19	0.67
Education (years)	16.8 ± 2.5	16.7 ± 2.1	16.8 ± 1.8	26.0	0.98
Race
Asian	2 (6.1%)	1 (6.7%)	0 (0.0%)	0.71	0.40
Black	12 (36.4%)	9 (60%)	3 (50.0%)	0.42	0.52
White	17 (51.5%)	4 (26.7%)	2 (33.3%)	0.23	0.63
Other	2 (6.1%)	1 (6.7%)	1 (16.7%)	1.61	0.20
Diagnosis
MDD	26 (78.8%)	11 (73.7%)	5 (83.3%)	0.51	0.47
Dysthymia	2 (6.1%)	1 (6.7%)	0 (0.0%)	0.71	0.40
Depression NOS	5 (15.2%)	3 (20%)	1 (16.75)	0.07	0.79
Duration of Current Depressive Episode (weeks)	634.5 ± 977.5	582.9 ± 999.7	538.0 ± 875.5	12.0	0.81
Number of Prior Antidepressant Medications	0.9 ± 1.4	0.3 ± 0.7	0.3 ± 0.5	4.5	1.00
Baseline CGI–S	3.6 ± 0.8	3.4 ± 0.8	3.3 ± 1.0	27.0	1.00
Baseline CES–D	26.5 ± 11.3	21.7 ± 11.3	20.0 ± 8.9	23.0	0.67
Baseline HRSD	20.7 ± 6.6	17.5 ± 5.8	16.5 ± 6.9	25.0	0.84
ΔHRSD	–	−7.8 ± 7.1	−5.8 ± 10.3	23.5	0.71
Baseline Digit Symbol	36.8 ± 10.7	30.0 ± 8.8	35.8 ± 10.1	10.0	0.05
ΔDigit Symbol	–	9.6 ± 8.2	7.0 ± 5.3	17.5	0.28
Baseline Gait Speed (m/s)	0.97 ± 0.10	0.77 ± 0.19	0.77 ± 0.15	24.0	0.72
ΔGait Speed (m/s)	–	0.10 ± 0.13	0.05 ± 0.10	18.0	0.29

Values are mean ± standard deviation or N (%).

CGI–S clinical global impressions–severity, CES–D center for epidemiological studies–depression, HRSD Hamilton rating scale for depression, NOS not otherwise specified.

^aComparison between subjects treated with L-DOPA with follow-up NM-MRI and those without follow-up NM-MRI.